Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture
NCT ID: NCT05877066
Last Updated: 2024-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
130 participants
OBSERVATIONAL
2023-06-14
2024-02-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Researchers will collect real-world data (RWD), based on usual care, to gain a more in-depth knowledge of the natural history and the treatment outcomes of Dupuytren's Contracture (DC) to evaluate the management of DC.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment
NCT01715467
Percutaneous Aponeurotomy in the Treatment of Dupuytren's Disease
NCT02474576
Splinting for Dupuytren's Contracture Release
NCT00575458
Preoperative Serial Casting, Education, and Therapy for Dupuytren's Contracture
NCT07024576
Post-contracture Release Radiation for Dupuytren's Disease
NCT04122313
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years (or age of majority in their jurisdiction) or older at time of enrollment.
* Willing to participate in the registry (including completion of ePROs) and complete the informed consent form.
* Having received DC treatment, either non-surgical or surgical, within 2 weeks before enrollment, at enrollment or any time after the date of enrollment or not having received DC treatment after confirmed diagnosis of DC.
* Able to participate in English based registry.
Exclusion Criteria
* Age less than 18 years.
* Do not provide informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pulse Infoframe
INDUSTRY
Endo Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Information
Role: STUDY_DIRECTOR
Endo Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Endo Pharmaceuticals Clinical Site 6
Phoenix, Arizona, United States
Endo Pharmaceuticals Clinical Site 5
Greenwich, Connecticut, United States
Endo Pharmaceuticals Clinical Site 4
Temple Terrace, Florida, United States
Endo Pharmaceuticals Clinical Site 2
Indianapolis, Indiana, United States
Endo Pharmaceuticals Clinical Site 1
Eatontown, New Jersey, United States
Endo Pharmaceuticals Clinical Site 7
Charlotte, North Carolina, United States
Endo Pharmaceuticals Clinical Site 3
Bend, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EP01REG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.